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Abstract
Introduction: In several studies, the chimeric antigen receptor T-cell therapy tisagen-
lecleucel demonstrated encouraging rates of remission and lasting survival benefits in 
pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). 
We assessed the cost-effectiveness of tisagenlecleucel (list price: 320 000 EUR) 
among these patients when compared to clofarabine monotherapy (Clo-M), clofara-
bine combination therapy (Clo-C), and blinatumomab (Blina) from both a healthcare 
and a societal perspective. We also assessed future medical and future non-medical 
consumption costs.
Methods: A three-state partitioned survival model was used to simulate a cohort of 
pediatric patients (12 years of age) through different disease states until the end of 
life (lifetime horizon). Relevant outcomes were life years, quality-adjusted life years 
(QALYs), healthcare costs, societal costs, and the incremental cost-effectiveness ratio 
(ICER). Uncertainty was explored through deterministic and probabilistic sensitivity 
analyses as well as through several scenario analyzes.
Results: Total discounted costs for tisagenlecleucel were 552 679 EUR from a so-
cietal perspective, which was much higher than the total discounted costs from a 
healthcare perspective (ie, 409 563 EUR). Total discounted societal costs for the 
comparator regimens ranged between 160 803 EUR for Clo-M and 267 259 EUR for 
Blina. Highest QALYs were estimated for tisagenlecleucel (11.26), followed by Blina 
(2.25), Clo-C (1.70) and Clo-M (0.74). Discounted societal ICERs of tisagenlecleucel 
ranged between 31 682 EUR/QALY for Blina and 37 531 EUR/QALY for Clo-C and 
were considered cost-effective with a willingness-to-pay (WTP) threshold of 80 000 
EUR/QALY. None of the scenarios exceeded this threshold, and more than 98% of 
the iterations in the probabilistic sensitivity analysis were cost-effective.
Discussion: At the current price and WTP threshold, tisagenlecleucel is cost-ef-
fective from both a healthcare and a societal perspective. Nevertheless, long-term 
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1  | INTRODUC TION
With current first-line treatment protocols, survival in pediatric 
B-cell acute lymphoblastic leukemia (pALL) increased to 85%-90% 
over the past years. Also in relapsed pALL, 40%-60% of children 
can be cured with intensive chemotherapy regimens, often includ-
ing allogeneic stem cell transplantation (alloSCT).1 The prognosis for 
patients with a second relapse, with a relapse after alloSCT, or with 
refractory pALL remains however poor, ranging from 10% to 30% 
2-year overall survival (OS).2,3 In this article, these patients are re-
ferred to as r/r pALL patients. Current regimens for r/r pALL include 
clofarabine monotherapy (Clo-M), clofarabine combination therapy 
(Clo-C), and blinatumomab (Blina), although no clearly defined stand-
ard of care yet exists. In countries such as the United States and the 
UK, salvage chemotherapy is also commonly used.
In several clinical trials, the chimeric antigen receptor (CAR) 
T-cell therapy tisagenlecleucel showed high rates of remission4-8 
and lasting survival benefits with 12-month event-free survival (EFS) 
rates between 45% and 51%.4,5,7 These promising results come at a 
high costs however. In the United States, tisagenlecleucel was made 
available at 475 000 USD (approx. 414 000 EUR) which included an 
outcome-based commercial model.9 The stated list price in the UK is 
282 000 GBP (314 000 EUR; 360 000 USD), and after a confidential 
discount, it is currently available via the Cancer Drug Fund.10 In the 
Netherlands, the list price is 320 000 EUR. Whether tisagenlecleu-
cel is a cost-effective alternative to existing treatments is a pressing 
question for policymakers, payers, clinicians and patients and can be 
explored by cost-effectiveness modeling approaches.11 Ideally, such 
a cost-effectiveness analysis is not limited to a healthcare (or payer) 
perspective, including only direct healthcare costs. This is because 
treatment for r/r pALL also affects both personal and professional 
lives of the patients and their caretakers. When other aspects such 
as travel costs, informal care costs, and productivity losses or gains 
are incorporated, a cost-effectiveness study is referred to as being 
conducted from a so-called “societal perspective.” The Dutch EE 
guideline recommends such a perspective for all cost-effectiveness 
analyses in the Netherlands.12
To date, some economic evaluation studies have been performed 
estimating the cost-effectiveness of tisagenlecleucel compared to 
Clo-M, Clo-C, or Blina over a lifetime horizon (ie, until all simulated 
patients died).13-17 All of them found tisagenlecleucel cost-effective 
in at least one scenario from a payer perspective14,16,17 and a societal 
perspective.13,15 To employ a societal perspective, Sarkar et al13 in-
cluded cost of caregivers, patient time, transportation, and parking, 
as well as meals. However, it remains unclear what specific cost items 
were considered with regard to caregivers and patient time. The ini-
tial manufacturer submission to the Canadian Agency for Drugs and 
Technologies in Health (CADTH) did not seem to include a societal 
perspective. Therefore, the CADTH considered travel and accom-
modation time for patients and caregivers, medical coinsurance 
amounts, copayment, and deductibles over a period of only 3 years 
for a scenario analysis from a societal perspective.15 Assuming a life-
time horizon for the economic model, the considered total societal 
costs for tisagenlecleucel of approximately 16 500 CAD seem to be 
a drastic underestimation of the true societal costs that can be at-
tributed to tisagenlecleucel in the lifetime of pediatric patients.
Our aim was to add to the existing evidence for tisagenlecleucel 
in r/r pALL patients by estimating the cost-effectiveness of tisagen-
lecleucel for pediatric patients with r/r pALL from a broad societal 
perspective when compared to Clo-C, Clo-M, and Blina, respec-
tively. We are the first study to consider both medical and non-med-
ical consumption costs in life years gained (ie, future medical costs). 
Furthermore, we considered productivity losses for patients’ care-
takers rather than for the pediatric patients and explored the inclu-
sion of potential productivity gains for children with long-term EFS.
2  | METHODS
The primary outcome of this analysis was the incremental cost-
effectiveness ratio (ICER) of tisagenlecleucel for each comparator 
from two perspectives over a lifetime horizon.12 A healthcare per-
spective included costs and effects of pretreatment, treatment, 
adverse events, follow-up period, subsequent HSCT, and future 
medical costs. A societal perspective included all costs and effects 
of the healthcare perspective in addition to costs for travel, the stay 
of caregivers at a charity hotel during treatment, productivity losses 
effectiveness data are needed to validate the several assumptions that were neces-
sary for this model.
K E Y W O R D S
CAR-T, cost-effectiveness, pediatric ALL, tisagenlecleucel
Novelty statement
• This is the first European cost-effectiveness analysis of 
tisagenlecleucel from a societal perspective.
• Tisagenlecleucel is cost-effective from both a health-
care and a societal perspective.
• Our findings may be used to support decision-mak-
ing in both clinical application and reimbursement of 
tisagenlecleucel.
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of patients’ caregivers, and informal care. Lastly, we also considered 
non-medical consumption costs.18,19 Results of all perspectives are 
reported separately. The base case is defined from a societal per-
spective, including future non-medical consumption costs as this 
represents the most conservative estimates.
To estimate the clinical effectiveness outcomes such as life years 
(LYs) and quality-adjusted life years (QALYs) of each treatment, we 
modeled a fictive cohort of pediatric patients (12 years of age) that 
receive tisagenlecleucel or either comparator treatment (ie, Clo-M, 
Clo-C, or Blina). At any time, the modeled patients could be in one 
of the three health states: (a) EFS, (b) progressive disease (PD), or 
(c) death (see Figure 1). The proportion of patients per health state 
was estimated from standard parametric survival functions (ie, ex-
ponential, Weibull, log-logistic, log-normal, Gompertz, and general-
ized Gamma) with the best statistical and clinical fit to the observed 
OS and EFS.20 In addition, a set of flexible cubic spline models was 
considered to capture the potential curative nature of tisagenlecleu-
cel.21 Statistical fit was assessed with Akaike information criterion 
(AIC) and the Bayesian information criteria (BIC), while clinical plau-
sibility was validated by a clinical expert (PMH). For tisagenlecleu-
cel, survival (EFS and OS) was based on pooled data (N = 193) from 
the ELIANA (NCT02435849), ENSIGN (NCT02228096), and B2101J 
(NCT01626495) trials.22-24 Overall survival for Clo-M,25 Clo-C,26 and 
Blina3 was based on the literature. Since EFS data were not available 
for the comparator arms, EFS was considered proportional to OS, 
using a validated ratio from the literature.27
Patients who remained in the EFS state after 5 years were as-
sumed to be long-term survivors of ALL (ie, considered cured). This 
assumption was based on the observed plateau phase and validated 
by expert opinion. OS of these patients was modeled by applying 
the standard mortality rate (SMR) of 15.2 for 5-year ALL survivors.28 
The initial proportional relationship of EFS to OS was assumed for 
the first 5 years of the model. After the fifth year, the cumulative 
survival probabilities of EFS were assumed to flatten up until they 
reached OS. In the model, EFS could not exceed OS at any time 
point. Furthermore, we assumed that relapses and leukemia-specific 
deaths only occurred within the first 5 years for all comparators.
The model cycle length was set to 1 month. To adhere to the 
Dutch guideline for economic evaluation research (Dutch EE guide-
line), costs and effects were discounted at a 4% and 1.5% rate, 
respectively.12,29
Tisagenlecleucel was included as a one-time infusion costing 
€320 000, and its dosing schedule was according to the ELIANA 
trial.22 For the comparator treatments, dosing schedules were taken 
from the literature.3,26,30 Adverse treatment events (AEs) were con-
sidered for all treatments and included cytokine release syndrome 
and B-cell aplasia. After initial therapy, we assumed that a propor-
tion of patients would receive HSCT (17%, 16%, 40%, and 34% for 
tisagenlecleucel, Clo-M, Clo-C, Blina, respectively). For patients 
staying alive (ie, in EFS or PD), we assumed follow-up costs for out-
patients visits and laboratory test and procedures with different re-
source use frequencies per model health state (see Appendix S1).
To calculate QALYs, health-state utilities for EFS and PD were 
derived from the EQ-5D-3L data collected in the ELIANA trial and 
estimated with the Dutch tariff.22,31 Additional disutilities (ie, for 
treatment and adverse events) and age-related utility decrements 
were based on the literature.32-34
Prices and costs for the societal perspective were based on the 
Dutch EE guideline and the literature (see Table 1 and Appendix 
S1).12,35 Future costs (medical and non-medical consumption) were 
based on the PAID tool (version 3.0).36 Furthermore, we explored 
potential productivity gains due to the improved survival by assum-
ing that 53% of the long-term survivors aged 18 years or older would 
be employed.37 These cost savings were explored in a scenario anal-
ysis to account for potential future productivity gains.
Lastly, we conducted deterministic sensitivity analyses (DSA), 
probabilistic sensitivity analysis (PSA) to address uncertainty of the 
model input parameters and estimates (see Table 1). Several scenario 
analyses were performed to explore the influence of different as-
sumptions on the ICER.
A list of key input parameters to the model including their source 
is presented in Table 1, and a more detailed description of the em-
ployed methodology can be found in the Appendix S1.
3  | RESULTS
In the model base case, tisagenlecleucel yielded 14.01 discounted 
LYs and 11.26 discounted QALYs, which was much higher than any 
of the comparators. Undiscounted LYs and QALYs were 18.98 and 
15.21, respectively. Figure 2 shows the observed EFS from the 
pooled data as well as the modeled EFS of all treatments. Figure 3 
shows both observed and modeled OS of all treatments.
The total discounted treatment costs for tisagenlecleucel were 
338 122 EUR and included costs for drug acquisition and administra-
tion as well as outpatient and inpatient days. These costs were the 
highest when compared to any comparator regimen (Clo-M: 73 457 
EUR, Clo-C: 39 745 EUR, Blina: 119 931 EUR). The main cost driver 
were the much higher drug acquisition costs for tisagenlecleucel 
(320 000 EUR), when compared to all other drugs (See Table 1). Only 
for tisagenlecleucel was a pretreatment regimen (ie, lymphodeplet-
ing regimen) necessary. Total discounted costs for this pretreatment 
were 6821 EUR, with drug acquisition costs (ie, for fludarabine, 
cyclophosphamide, cytarabine, or etoposide) being the main cost 
driver. Considering both pretreatment and treatment costs of ti-
sagenlecleucel together, the total treatment costs amounted to F I G U R E  1   De novo model
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TA B L E  1   Model input parameters and values
Variable Value
Measurement of uncertainty in 
DSA and PSA
Distribution used 
in PSA Source
Model settings
Discount rate (costs) 4.00% NA NA Dutch EE guideline12
Discount rate (benefits) 1.5% NA NA
Time horizon 88 y NA NA NA
Patient characteristics
Starting age (years) 12 95% CI: 1; 25 Normal Pooled data
Percent female 46.63% SE: 0.04 Beta
Mean body surface area (BSA) 1.3 SE: 0.03 Normal
Mean weight (kg) 41.7 SE: 1.52 Normal
Efficacy
OS distribution Log normal Different distributions selected 
in DSA
Bootstrapped Assumption validated by 
clinical expertEFS distribution Gompertz
Duration of benefit in months 60 NA NA
EFS vs OS ratio for all 
comparators
0.69 SE: 25% of mean Beta Van den Berg et al, 2011
Drug and procedure acquisition cost
Pretreatment cost for 
lymphodepleting regimen
€521 SE: 25% of mean Gamma ELIANA trial (resource use); 
Dutch Z-index (unit cost)
Tisagenlecleucel €320 000 Dutch Z-index public list price
Clofarabine monotherapy €71 020 Jeha et al 2006 (dosing 
schedule); Dutch Z-index 
(unit cost)
Clofarabine combination 
therapy
€35 453 Hijiya et al 2011 (dosing 
schedule); Dutch Z-index 
(unit cost)
Blinatumomab €117 934 von Stackelberg 2016 (dosing 
schedule); Dutch Z-index 
(unit cost)
Inpatient and outpatient administration cost
Pretreatment cost for 
lymphodepleting regimen
€6301 SE: 25% of mean Gamma ELIANA (resource use); Dutch 
EE guideline and Franken 
et al, (unit cost inpatient and 
daycare respectively)
Tisagenlecleucel €15 932  
Clofarabine monotherapy €2437 Clinical expert opinion 
(resource use); Franken et al, 
2018 (unit cost)
Clofarabine combination 
therapy
€4292 Clinical expert opinion 
(resource use); Dutch EE 
guideline (unit cost)
Blinatumomab €1997 Clinical expert opinion 
(resource use); Franken 
et al, 2018 (unit cost); von 
Stackelberg et al 2016 
(distribution of patients over 
treatment cycles)
Subsequent HSCT
(Continues)
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Variable Value
Measurement of uncertainty in 
DSA and PSA
Distribution used 
in PSA Source
Rates for tisagenlecleucel 16.58% SE: 25% of mean Beta pooled data, (duration and 
percentage)
Rate for clofarabine 
monotherapy
16.39% SE: 0.07 Evoltra product label (duration 
and percentage)
Rate for clofarabine 
combination therapy
40.00% SE: 0.05 Hijiya et al 2011 (duration and 
percentage)
Rate for blinatumomab 34.29% SE: 0.10 von Stackelberg et al 2016 
(duration and percentage)
Disutility (treatment) -0.21 SE: 25% of mean Beta Forsythe et al, 2018
Disutility (6-12 mo after 
treatment)
-0.02
Costs: stem cell harvestinga  €66 581 SE: 25% of mean Gamma Blommestein et al, 2012
Costs: initial HSCT procedurea  €44 391
Follow-up costs after HSCT 
(up to 1 y) a 
€106 618
Health-state utilities and disutilities
Utility for EFS 0.83 SE: 0.03 Beta ELIANA trial
Utility for PD 0.68 SE 0.05
Disutility for tisagenlecleucel 
(duration in days)
-0.20 (26) SE: 25% of mean Kwon et al 2018 (utility 
value)33; Gaynon et al 2006 
(duration Clo-M)47; Hijiya 
et al 2011 (duration (Clo-
C)26; von Stackelberg 
et al 2016 (duration Blina)3
Disutility for Clo-M (duration 
in days)
-0.20 (66)
Disutility for Clo-C therapy 
(duration in days)
-0.20 (47)
Disutility for Blina (duration 
in days)
-0.20 (61)
Age-related utilities Age < 25:0.95
Age 25-74:0.93 
- 0.89
Age 75+: 0.83
NA Janssen et al 201434
Future costs
Future medical costs Various costs per 
treatment and 
age group
NA NA Van Baal et al, 201119
Future non-medical 
(consumption) costs
Various costs per 
treatment and 
age group
NA NA  
Patient and family costs
Distance to hospital 79 kilometers NA NA Own calculation
Travel costsb  €3.09 parking 
costs per visit, 
€0.19 per 
kilometer for 
travelling by car
NA NA Dutch EE guideline12
Average number of 
caregivers/ parents 
accompanying patient
1.5 NA NA Expert opinion
Parents stay at a charity hotel 
during treatment
€60 NA NA Charity hotel website (Ronald 
McDonald)
TA B L E  1   (Continued)
(Continues)
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344 943 EUR (discounted). Discounted costs for adverse events 
were highest for tisagenlecleucel (24 731 EUR), when compared to 
Clo-M (4269 EUR), Clo-C (8085 EUR), and Blina (4210 EUR). This was 
mainly due to the relatively high prevalence of B-cell aplasia and the 
associated high costs of IVIG.
From a healthcare perspective, considering all discounted 
cost for treatment (including pretreatment for tisagenlecleucel), 
adverse events, follow-up period, subsequent HSCT, and future 
medical costs of unrelated diseases, the total healthcare costs for 
tisagenlecleucel was 409 563 EUR. This was nearly four times as 
much when compared to Clo-M (113 937 UER) or Clo-C (136 069 
EUR) and more than double the total healthcare costs of Blina 
(200 293 EUR).
For a societal perspective, we added costs of caretakers’ pro-
ductivity losses, travel costs (for both caretakers and patients), 
informal care for patient below the age of 18 years, and caretak-
ers’ stay at a charity hospital during the treatment period to the 
healthcare perspective. The total discounted costs from this per-
spective were 488 340 EUR for tisagenlecleucel, and 156 909 
EUR, 182 496 EUR and 253 024 EUR for Clo-M, Clo-C, and Blina, 
respectively. Major cost drivers in all perspectives were the total 
costs of treatment for tisagenlecleucel, Clo-M, and Blina. Only for 
Clo-C, subsequent HSCT was more expensive than the treatment 
costs. When non-medical consumption costs were added to the so-
cietal perspective, total costs increased for all treatment options. 
Total discounted costs for tisagenlecleucel, Clo-M, Clo-C, and Blina 
were 552 679 EUR, 160 803 EUR, 193 920 EUR, and 267 259 EUR, 
respectively.
When comparing total discounted costs of the healthcare per-
spective to the societal perspective, costs increased most for tis-
agenlecleucel (78 777 EUR), followed by Blina (42 972 EUR), Clo-C 
(46 427 EUR), and Clo-M (52 731 EUR). Considering future non-med-
ical consumption as part of the societal perspective, the additional 
costs when compared to the healthcare perspective were 143 116 
EUR, 66 966 EUR, 57 851 EUR, and 46 866 EUR for tisagenlecleucel, 
Clo-M, Clo-C, and Blina, respectively.
The discounted ICERs per QALY gained, comparing tisagenle-
cleucel to Clo-M, Clo-C, and Blina from a healthcare perspective 
were 27 443 EUR, 28 611 EUR, and 23 229 EUR, respectively. When 
taking a societal perspective, the ICERs increased to 30 767 EUR/
QALY, 31 996 EUR/QALY, and 26 120 EUR/QALY comparing tis-
agenlecleucel to Clo-M, Clo-C, and Blina, respectively. When future 
non-medical consumption costs were added, ICERs of tisagenlecleu-
cel compared to Clo-M, Clo-C, and Blina were 36 378 EUR/QALY, 
37 531 EUR/QALY, and 31 682 EUR/QALY. Assuming a WTP thresh-
old of 80 000 EUR/QALY gained, it can thus be concluded that tis-
agenlecleucel is a cost-effective treatment when compared to any 
comparator examined in this study.
The estimation of potential lifetime productivity gains could be 
202 563 EUR, 482 EUR, 8884 EUR, and 12 658 EUR per patient for 
tisagenlecleucel, Clo-M, Clo-C, and Blina. However, it needs to be 
noted that these estimates are subject to substantial uncertainty as 
Variable Value
Measurement of uncertainty in 
DSA and PSA
Distribution used 
in PSA Source
Informal carec  € 14.52 per 
hour, 8 h per 
outpatient 
visit, daycare 
treatment, or 
inpatient hospital 
day
NA NA Dutch EE guideline12
Productivity losses
Total productivity losses 
females
€ 12 499 SE: 25% of meanb  Gammad  Dutch EE guideline12 (wage 
per hour)
Total productivity losses males € 8993
Rate of females with 
productivity losses
60% Hovén et al, 201348 
(proportion of parents going 
back to work) Statistics 
Netherlands (proportion of 
parents contributing to the 
labor force)
Rate of males with 
productivity losses
85%
Abbreviations: Allo-SCT, allogeneic stem cell transplantation; CI, confidence interval; MUD, matched unrelated donor; NA, not applicable; SE, 
standard error; sib, sibling donor; UCB, umbilical cord blood.
aBased on proportions for different HSCT type (see Appendix S1) 
bThe amount of travel trips is dependent on the assumed treatment regimen and respective number of visits during treatment and follow-up visits 
(see Appendix S1 for treatment schedules and follow-up visit frequencies). 
cInformal care was assumed for patients aged < 18 y. 
dOnly total costs of the productivity losses were varied in both DSA and PSA (ie, a combination of the rate and the costs). 
TA B L E  1   (Continued)
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explained in the discussion and are therefore not considered for any 
presented ICER.
All deterministic results of the cost-effectiveness analysis are 
presented in Table 2.
Deterministic sensitivity analyses demonstrated that the varia-
tion of the starting age of the simulated cohort was the most influ-
ential factor for the ICER in all three comparators. Figure 4 depict 
the top 10 DSA results of ICERs per QALY for each comparator 
treatment in so-called Tornado diagrams. Although the change in 
some parameters affected the ICER quite heavily, none of the cal-
culation exceeded an ICER of 45 000 EUR per QALY gained. The 
impact of choosing different parametric survival models for OS 
and EFS and the impact of choosing different time horizons were 
tested in scenario analyses. Depending on the chosen parametric 
survival function for EFS, different proportions of cured patients 
were estimated. In this case, we refer to cured patients as those 
who stay in EFS 5 years after treatment until the end of life. The 
proportion of cured patients 5 years post-treatment varied be-
tween 8% (exponential distribution for EFS) and 40% (log-normal 
distribution). Choosing either parametric survival function (both 
for OS or EFS) did not cause the ICER to exceed the WTP thresh-
old of 80 000 EUR per QALY gained.
Results of the 5000 PSA iterations (societal perspective, includ-
ing future non-medical consumption) are depicted in the cost-effec-
tiveness (CE) plane in Figure 5. The average ICERs per QALY gained 
were in line with the deterministic results with 38 129 EUR, 42 289 
EUR, and 34 564 EUR when compared to Clo-M, Clo-C, and Blina, 
respectively. At a WTP threshold of 80 000 EUR, the probability of 
all simulations being cost-effective for Clo-M, Clo-C, and Blina was 
100%, 98%, and 100%, respectively.
Of the conducted scenario analyses, assuming a time horizon 
of 20 years had the highest impact on the ICER. In this scenario, 
the ICERs per QALY gained increased to 60 859 EUR, 63 341 EUR, 
and 53 698 EUR for Clo-M, Clo-C, and Blina, respectively. This im-
plies that tisagenlecleucel is less cost-effective with a shorter time 
horizon.
Assuming a plateau phase in EFS after 3 years (instead of 5 years) 
decreased the ICER per QALY gained to 31 798 EUR, 33 641 EUR, 
and 29 219 EUR for Clo-M, Clo-C, and Blina, respectively. This sug-
gests that the sooner patients can be considered cured with tisagen-
lecleucel, the more cost-effective the treatment is.
Our analyses also show that the prevalence of B-cell aplasia sub-
stantially adds to the costs of the tisagenlecleucel treatment, mainly 
through the length of IVIG usage. Based on the literature, we assumed 
an average duration of B-cell aplasia of 11.4 months. Testing this as-
sumption in a scenario analysis and considering IVIG cost for the en-
tire duration of EFS among those without subsequent HSCT increased 
the ICER to 49 969 EUR/QALY, 52 847 EUR/QALY, and 47 932 EUR/
QALY gained for Clo-M, Clo-C, and Blina, respectively. Hence, a lon-
ger treatment duration with IVIG negatively affected the ICER.
F I G U R E  2   EFS extrapolated (and observed for tisagenlecleucel)
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4  | DISCUSSION
Our results showed that assessing the cost-effectiveness of tisa-
genlecleucel from a societal perspective as opposed to a healthcare 
perspective, increased all estimated total costs and ICERs. This was 
due to the relative higher increase in total costs for tisagenlecleucel 
when compared to Clo-M, Clo-C, or Blina. Nevertheless, we dem-
onstrate that tisagenlecleucel is also cost-effective for pediatric pa-
tients with relapsed/refractory B-cell acute lymphoblastic leukemia 
from a societal perspective. Although all efficacy input parameters 
for the model stem from international clinical studies, background 
mortality and HRQoL data as well as all costs were analyzed from a 
Dutch perspective. Transferability to an international setting needs 
therefore to be considered with caution.
Nevertheless, considering all assumptions made, our model re-
sults can be regarded as robust: all explored scenarios rendered ti-
sagenlecleucel cost-effective with a WTP threshold of 80 000 EUR 
per QALY gained. In addition, all 5000 iterations of the PSA yielded 
a probability for tisagenlecleucel being cost-effective of more than 
98%. The deterministic sensitivity analysis showed that the cohort 
starting age together with the utility values for EFS and the assumed 
subsequent HSCT rates for the comparator treatment had the high-
est impact on the results. However, when any of these parameters 
were altered (ie, increased or decreased in their estimated value), 
none of them had the potential to bring the ICER above 48 000 EUR/
QALY gained. Lastly, the conducted scenario analyses demonstrate 
an increase in the ICER with decreasing time horizons (ie, follow-up 
time) and a considerable impact of the IVIG assumption (ie, how long 
IVIG is given) on the ICER.
The favorable results for tisagenlecleucel in our analysis can 
mainly be explained by the extensive survival gains when compared 
to other treatment options. With a total of 14.01 life years (dis-
counted), tisagenlecleucel performed significantly better than any 
of the comparators. Since to date no randomized clinical trials for 
tisagenlecleucel in r/r ALL patients exist, the modeled effectiveness 
was based on single-arm studies. Furthermore, no information about 
EFS was available in the publications of the comparative treatments. 
Based on a high correlation between EFS and OS,38 we assumed that 
the missing EFS data could be estimated based on the available OS 
data. This may have influenced the EFS estimates of the comparative 
treatments.
According to the currently available evidence, tisagenlecleu-
cel is a potential curative treatment thereby preventing young pa-
tients from premature death. Consequently, substantial life years 
and QALYs can be gained from a lifetime perspective. However, it 
needs to be noted that the long-term effects of tisagenlecleucel 
are not yet captured by any study, registry, or clinical trial, because 
none of those have lifetime follow-up data. We assumed no specific 
late side effects after tisagenlecleucel and regarded patients to be 
cured after 5 years. In our model, patients that remain in EFS for 
F I G U R E  3   OS observed and extrapolated
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5 years after treatment are considered being cured. This assumption 
helped to reduce some of the long-term uncertainties arising from 
long-term survival extrapolation data beyond the observed trial 
data. The 5-year cut-off was validated by clinical experts and our 
approach was similar to the one used for the National Institute for 
Health and Care Excellence (NICE) mock technology appraisal for 
chimeric antigen receptor T-cell (CAR-T) therapy as a treatment for 
r/r B-cell pALL.39 However, the exact time at which patients in long-
term EFS may be considered cured is uncertain. In a scenario analy-
sis, we explored the impact of assuming three instead of 5 years as 
a cut-off. Consequently, all ICERs decreased (ICER Clo-M: 29 628 
EUR/QALY, ICRE Clo-C: 31 459 EUR/QALY, ICER Blina: 27 110 EUR/
QALY gained), meaning that the sooner patients can be considered 
cured, the more cost-effective tisagenlecleucel is. Irrespective of 
the time point at which patient may be considered cured, it is un-
certain what fraction of patients can be considered disease free at 
that time. Up until the 5 years after treatment, the EFS in the model 
was based on parametric survival functions. Each of these func-
tions estimated different probabilities for EFS 5 years after treat-
ment start. These estimates ranged between 8% and 40% for EFS, 
but none of these scenarios exceeded an ICER of 45 000 EUR per 
QALY gained. Nonetheless, empirical long-term follow-up data are 
vital to reduce uncertainty in effectiveness outcomes. Data from 
patient registries such as the EBMT (European Society for Blood and 
Marrow Transplantation) registry may play a vital role in collecting 
the necessary information.
The estimated favorable survival outcomes (both in EFS and OS) 
indicate significant benefits for both patients and society. These 
can best be captured by extending the healthcare perspective to a 
societal perspective. Assuming a societal perspective made it pos-
sible to capture costs from a broad economic angle, including the 
impact of the treatment on patients and their families. To include 
these additional cost components, health economic researchers can 
choose from an abundance of validated methodological approaches 
in the literature or health economic guidelines. However, most of 
the available approaches only focus on adult patient populations and 
children as well as young adults remain understudied.40-44 Costs of 
productivity losses (ie, the costs occurring when the productivity of 
individuals is affected by illness, treatment, disability, or premature 
death) for instance may be relevant to patients that already were 
(economically) productive before the onset of the disease.45 In the 
case of most pediatric ALL patients, this is however not the case. 
Instead, patients’ parents or caregivers face these losses. Since 
Dutch-specific data were unavailable concerning the productivity 
losses of parents and informal care, we made assumptions based 
upon available information in the literature.
TA B L E  2   Deterministic results of the model base case
Item
Treatment
Tisagenlecleucel
Clofarabine 
monotherapy
Clofarabine combination 
therapy Blinatumomab
Costs
Pretreatment €6821 - - -
Treatmenta  €338 122 €73 457 €39 745 €119 931
Adverse events €24 731 €4269 €8085 €4210
Follow-up €3811 €540 €1204 €1549
Subsequent HSCT €36 077 €35 670 €87 036 €74 602
Patient and family €14 277 €2627 €2733 €3319
Productivity losses €28 301 €25 868 €26 857 €30 696
Future medical costs (unrelated 
disease and consumption)
€100 538 €18 371 €28 262 €32 952
Total costs €552 679 €160 803 €193 920 €267 259
Effects
Life years 14.01 0.74 2.46 3.17
Quality-adjusted life years 11.26 0.49 1.70 2.25
Increments (tisagenlecleucel vs each comparator)
Costs - €391 876 €358 759 €285 420
Life years - 13.27 11.55 10.84
Quality-adjusted life years - 10.77 9.56 9.01
ICERs
Costs per life years gained - €29 535 €31 052 €26 334
Costs per quality-adjusted life year 
gained
- €36 378 €37 531 €31 682
aThe treatment costs entail drug/procedure costs, and costs for the inpatient and outpatient visits. 
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For economic evaluations conducted from a US or Dutch perspec-
tive, it is recommended to consider future medical costs. 12,46 While the 
US guidelines recommend the inclusion future non-medical (consump-
tion) costs as well, the Dutch guideline does not mention its inclusion 
yet.12,46 Our study is the first to fully include both components in an 
evaluation of CAR T-cell therapy for pALL. Both aspects were added 
through the latest version of the iMTA PAID tool (version 3.0) which is 
available online (https://imta.shiny apps.io/PAID3 /). The methodology 
of this tool is described elsewhere.18,19 Due to the favorable survival 
of patients with tisagenlecleucel, the discounted future costs of this 
treatment were extensive (ie, 100 538 EUR), while these costs were 
significantly lower for Clo-M, Clo-C, or Blina (ie, 18 371 EUR, 28 262 
EUR, and 32 952 EUR, respectively). Long-term survivors of pALL may 
however not only induce costs in the future. Cured pediatric patients 
F I G U R E  4   Tornado charts
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may be able to finish their school education and consequently join the 
workforce. We refer to these prospects as potential productivity gains 
and made an attempt to quantify them in our analysis.
However, little is known about both educational and employ-
ment prospects of long-term survivors of childhood cancer. In ad-
dition, there is a lack of evidence and methodological guidance in 
how to integrate such gains in economic evaluations. Therefore, 
the inclusion of these cost savings in our model made use of rather 
simplistic assumptions and should be interpreted with caution. For 
instance, we assumed full and life-long employment of the modeled 
patients as from the age of 18 years. Future fluctuations on the job 
market or employment rates could not be reliably modeled and were 
beyond the scope of this research. Besides, it yet needs to be deter-
mined whether patients in long-term EFS can or will start on the job 
market once they attain majority. It is apparent that patients who 
can potentially be cured from ALL may be enabled to finish their 
education and join the workforce in the future. However, the here 
modeled patients were all relapsed or refractory to previous treat-
ment lines and non-attendance to school might have been significant 
during previous treatment lines. Research is needed to determine 
in how far the absence from school affects the job starting age and 
shapes future employment opportunities in this patient population. 
Furthermore, resulting from the uncertainty of the long-term ef-
fectiveness, no future productivity losses for the modeled patients 
were assumed that might result from long-term, disease-related 
absenteeism. Nevertheless, our approach may be seen as an illus-
tration of the magnitude of potential economic gains resulting from 
improved survival, especially in pediatric diseases. Further research 
could quantify the potential productivity gains by elucidating how 
this aspect can be captured and integrated into cost-effectiveness 
analyses in a sound methodological manner.
Although this study is not the first to estimate the cost-effective-
ness of tisagenlecleucel, it is the first to adopt a full societal perspec-
tive. Following a “mock appraisal” commissioned by the UK National 
Institute for Health and Care Excellence (NICE) to assess whether 
changed to its methods and processes were needed,39 several 
cost-effectiveness analyses were published in the US and Canada. 
Two studies had considered societal aspects in a scenario analysis, 
but none of them had considered productivity losses of caregivers, 
travel and hotel costs for patients and caregivers, informal care 
costs, and future medical costs including consumption costs alto-
gether.13,15 In addition, input parameters and outcomes of the soci-
etal perspective were either not reported,15 or not clearly defined 
and point to evidence of adult patients, while pediatric patients are 
studied (see patient time in Sarkar et al(2018)).13
When comparing our results to the other cost-effectiveness, 
studies we found some disparities. Differences in incremental 
costs were highest between our study and Sarkar et al13 for Clo-
C, followed by costs for Clo-M when compared to the NICE mock 
appraisal.39 The reason for these discrepancies can be explained 
by major differences in several cost input parameters. For instance, 
costs for tisagenlecleucel are higher in the United States when com-
pared to the Netherlands (475 000 USD [426 000 EUR] vs 320 000 
EUR). Similarity, the NICE mock appraisal assumed even higher one-
off costs for tisagenlecleucel of 528 600 GBP (587 697 EUR) per 
patient.39 In addition, estimated costs for HSCT in all US studies 
were significantly higher when compared to our study. Sarkar et al13 
assumed HSCT costs ranging between 299 987 USD (267 456 EUR) 
for successful HSCT and 459 682 USD (409 834 EUR) for failed 
HSCT. Lin et al14 estimated the HSCT costs to be 555 000 USD 
(483 904 EUR), which was similar to the estimates of Whittington 
et al16 (560 000 USD [488 264 EUR]). For every modeled patient that 
F I G U R E  5   CE-plane
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received subsequent HSCT, our model considered one-time costs of 
217 590 EUR per HSCT31 and no distinction was made between suc-
cessful or failed treatment.
With the exception for Whittington et al,16 incremental effects 
in LYs could be regarded as similar between all studies. Incremental 
QALYs differed to a greater extend and were highest for the study 
of Lin et al14 We hypothesize that this is mainly due to the use of 
different utility estimates. Lin et al14 used a variety of utility esti-
mates ranging between 0.56 and 0.92, depending on the health 
state or time. Our utility estimates were based on the ELIANA trial 
and ranged between 0.68 and 0.83, depending on the health states. 
Although we accounted for disutilities during any treatment, the 
stay at an intensive care unit, and graft-vs-host disease, our utilities 
were consistently higher when compared to Lin et al14
Finally, the divergent ICERs per QALY between the studies are 
a result of the difference in both costs and outcomes as explained 
above. Despite the several assumptions made in this study, we con-
clude that our results are robust (as tested through several sensitiv-
ity and scenario analyses) and that the conclusion of tisagenlecleucel 
being cost-effective is in line with all other cost-effectiveness stud-
ies for pediatric patients with r/r ALL. Furthermore, total costs from 
a societal perspective were higher for each treatment option when 
compared to costs from a healthcare perspective. Although the in-
crease in these costs was higher for tisagenlecleucel when compared 
to Clo-M, Clo-C, or Blina, none of the ICERs exceeded the WTP 
threshold of 80 000 EUR per QALY gained.
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